Soleno Therapeutics

Soleno Therapeutics, Inc. engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. The firm focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.

REDWOOD CITY, Calif., June  26, 2020  (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq: SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today the closing of its previously announced underwritten public offering of 34,848,484 shares of its common stock, including 4,545,454 shares sold upon full exercise of the underwriters’ option to purchase additional shares, at a public offering price of $1.65 per share. The net proceeds of the offering were approximately $53.7 million, after deducting the underwriting discount and other offering expenses.

Soleno Therapeutics Announces Closing of $57.5 Million Public Offering of Common Stock, Including the Full Exercise of Underwriters’ Option to Purchase Additional Shares

REDWOOD CITY, Calif., June  24, 2020  (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq:SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today the pricing of the underwritten public offering of 30,303,030 shares of its common stock at a public offering price of $1.65. Soleno has also granted the underwriters a 30-day option to purchase up to 4,545,454 additional shares of common stock, at the public offering price, less underwriting discounts and commissions.  The gross proceeds of the offering are expected to be approximately $50 million, before deducting the underwriting discount and other estimated offering expenses. The closing of the offering is expected to occur on or about June 26, 2020, subject to the satisfaction of customary closing conditions.

Soleno Therapeutics Announces Pricing of $50 Million Public Offering of Common Stock

Soleno (SLNO) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Soleno (SLNO) Looks Good: Stock Adds 6.8% in Session

Study Did Not Meet Statistical Significance for Primary Endpoint, but Showed Significant Improvements in Prespecified Subgroup with Severe Hyperphagia

Soleno Therapeutics Announces Top-line Results from Phase III Trial of DCCR for Treatment of Prader-Willi Syndrome

Investors need to pay close attention to Soleno Therapeutics (SLNO) stock based on the movements in the options market lately.

Implied Volatility Surging for Soleno Therapeutics (SLNO) Stock Options

Capnia, Inc. (SLNO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

Capnia, Inc. (SLNO) Moves to Buy: Rationale Behind the Upgrade

Soleno Therapeutics: A Promising Rare Disease Player For 2020

Soleno Therapeutics (SLNO) achieves enrollment target in the phase III study evaluating Diazoxide Choline Controlled-Release tablets for treating patients with Prader-Willi Syndrome. Stock up.

Soleno (SLNO) Ends Enrollment in Prader-Willi Syndrome Study

REDWOOD CITY, Calif., Oct.  25, 2019  (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the closing of its previously announced underwritten public offering of 12,841,667 shares of its common stock, including 1,675,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares, at a public offering price of $1.20 per share. The net proceeds of the offering were approximately $14.5 million, after deducting the underwriting discount and other offering expenses. 

Soleno Therapeutics Announces Closing of $15.4 Million Public Offering of Common Stock

REDWOOD CITY, Calif., Oct.  22, 2019  (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it intends to offer and sell shares of its common stock in an underwritten public offering.  The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Soleno Therapeutics  Announces Proposed Public Offering of Common Stock

REDWOOD CITY, Calif., Oct.  02, 2019  (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the Data Safety Monitoring Board (DSMB) has, for the second time, recommended the continuation without modification of the Company’s Phase III trial in Prader-Willi Syndrome (PWS) patients, DESTINY PWS.  The outcome of this second planned meeting was based on the review of data from more than 50% of patients enrolled and treated.

Soleno Therapeutics Announces Positive Outcome from Second Planned Data Safety Monitoring Board Review of Phase III DESTINY PWS Clinical Trial of DCCR in Prader-Willi Syndrome

Data Published for First Time in Peer-Reviewed Journal Data Published for First Time in Peer-Reviewed Journal

Soleno Therapeutics Announces Publication of Results from Previously Completed Phase II Trial of DCCR for Treatment of Prader-Willi Syndrome

REDWOOD CITY, Calif., Sept.  19, 2019  (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in one-on-one meetings with institutional investors at the Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Disease Companies, taking place September 23-24, 2019, in New York City.

Soleno Therapeutics to Participate in the Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Disease Companies

Capnia, Inc. (SLNO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Capnia, Inc. (SLNO) Upgraded to Strong Buy: Here's What You Should Know

As of late, it has definitely been a great time to be an investor Capnia.

Will Capnia to Surge Higher?

During Soleno Therapeutics' (SLNO) Q1 conference call, investor focus will be on its progress with the ongoing study on DCCR tablets, developed for the treatment of Prader-Willi syndrome.

Soleno Therapeutics (SLNO) to Post Q1 Earnings: What's Up?

Does Capnia, Inc. (SLNO) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why Capnia, Inc. (SLNO) is a Great Choice

Shares of thinly traded micro-cap biotech Soleno Therapeutics Inc (NASDAQ: SLNO) were surging Friday on over 700 times their average volume.

Soleno Therapeutics' 200% Spike: What You Need To Know

News for Soleno Therapeutics Stock (SLNO)